Avant Technologies and Austrianova Launch Klothonova, Begin Developing Age Related Cellular Therapies Using 'Longevity Protein' Klotho

Joint Venture Launch: Avant Technologies and Austrianova have launched Klothonova LLC, focusing on developing a genetically modified cell line that overexpresses the Klotho protein to create therapies for age-related diseases and promote longevity.

Research and Development Progress: Initial studies have successfully demonstrated the feasibility of using encapsulated genetically modified human cells to produce Klotho protein, paving the way for future preclinical and clinical studies.

GMP Compliance Commitment: Klothonova is prioritizing Good Manufacturing Practice (GMP) compliance to ensure the safety and quality of Klotho protein-producing cell lines, which is essential for advancing to clinical trials.

Market Potential: The joint venture aligns with the growing demand for cell-based therapies, with the market projected to reach $44 billion globally, highlighting the significance of Klotho's anti-aging properties.